Condition: Sezary Syndrome · Sponsor: Oleg E. Akilov, MD, PhD
The primary endpoint is to determine if ECP induces a decrease in % of tumor cells after treatment. 20 patients with Sezary Syndrome will receive ECP weekly x4, then bi-weekly for 5 months. Each patient will donate 5 samples to determine immune responses in peripheral blood. Additional clinical assessments will be a modified skin weighted assessment and flow cytometry at baseline and months 3 and 6. A CT scan will be obtained at baseline and only repeated if pathology is present at baseline. The tumor microenvironment will be studied by comparing transcriptomics of the blood samples before, 1 day after first ECP treatment, cycle 1, 1, 3 and 6 months after ECP treatment by scRNAseq (5 samples total per patient ).
This description comes directly from the study's public registry record.
Charity Ruhl, LPN · 4126472013 · ruhlcl@upmc.edu
Nicolena Verardi, PA-C · 412-864-3682 · verardin3@upmc.edu
Always discuss trial participation with your own doctor first.
| Emory University School of Medicine | Atlanta, Georgia, United States | Not Yet Recruiting |
| Cutaneous Translational Research Program - Johns Hopkins Medicine | Baltimore, Maryland, United States | Recruiting |
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05157581